EMERGENT BIOSOLUTIONS INC. Operating Lease, Right-of-Use Asset, Amortization Expense
EMERGENT BIOSOLUTIONS INC. (EBS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $500.00K, a 0.00% change year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $600.00K, a 0.00% change year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $400.00K, a 42.86% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $500.00K, a 44.44% decline year-over-year.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-06 | $1.10M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $600.00K 10-Q · filed 2026-05-01 | ||
| 2025-09-30 | $400.00K 10-Q · filed 2025-10-30 | $900.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.50M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-06 | $1.10M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-01 | ||
| 2024-09-30 | $700.00K 10-Q · filed 2025-10-30 | $1.60M derived: sum of 2 quarters · filed 2025-10-30 | $2.50M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $900.00K 10-Q · filed 2025-08-07 | $1.80M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $1.10M 10-Q · filed 2024-11-07 | $2.00M derived: sum of 2 quarters · filed 2024-11-07 | $3.10M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-07 | $2.00M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $1.40M 10-Q · filed 2023-12-11 | $2.80M derived: sum of 2 quarters · filed 2023-12-11 | $4.20M 10-Q · filed 2023-12-11 |
| 2022-06-30 | $1.40M 10-Q · filed 2023-08-09 | $2.80M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $1.40M 10-Q · filed 2023-05-10 | ||
| 2021-09-30 | $1.40M 10-Q · filed 2022-11-09 | $2.90M derived: sum of 2 quarters · filed 2022-11-09 | $4.20M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $1.50M 10-Q · filed 2022-08-02 | $2.80M 10-Q · filed 2022-08-02 | |
| 2021-03-31 | $1.30M 10-Q · filed 2022-04-29 | ||
| 2020-09-30 | $1.10M 10-Q · filed 2021-11-05 | $2.10M derived: sum of 2 quarters · filed 2021-11-05 | $3.20M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $1.00M 10-Q · filed 2021-07-30 | $2.10M 10-Q · filed 2021-07-30 | |
| 2020-03-31 | $1.10M 10-Q · filed 2021-04-30 | ||
| 2019-09-30 | $800.00K 10-Q · filed 2020-11-06 | $1.50M derived: sum of 2 quarters · filed 2020-11-06 | $2.10M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $700.00K 10-Q · filed 2020-07-31 | $1.30M 10-Q · filed 2020-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |